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Crimean-Congo Hemorrhagic Fever
By: Reuben Ninan
Introduction
The Crimean-Congo Hemorrhagic Fever (CCHF) is a tickborne infectious viral disease in the family Bunyaviridae. The
disease was first characterized in the Crimea in 1944 and given
the name Crimean hemorrhagic fever. CCHF was then later
recognized in 1969 as the cause of illness in the Congo, thus
resulting in the current name of the disease. CCHF causes
severe viral hemorrhagic fever outbreaks (CDC, 2014).
Ixodes scapularis (Black legged Ticks) before blood
indulgence

Location
Crimean-Congo hemorrhagic fever is found in Eastern Europe,
particularly in the former Soviet Union, throughout the
Mediterranean, in northwestern China, central Asia, southern
Europe, Africa, the Middle East, and the Indian subcontinent
(CDC, n.d.).

Symptoms
The onset of CCHF is sudden, with initial signs and symptoms
including headache, high fever, back pain, dizziness, neck pain
and/or stiffness, sore eyes, photophobia (sensitivity of light), joint
pain, stomach pain, and vomiting. Red eyes, a flushed face, a red
throat, and petechiae (red spots) on the palate are common.
Symptoms may also include jaundice (yellow color of the skin,
mucus membranes, or eyes), and in severe cases, changes in mood
and sensory perception (NCBI, n.d.).
As the illness progresses, large areas of severe bruising, severe
nosebleeds, and uncontrolled bleeding at injection sites can be seen,
with fatality rates in hospitalized patients have ranged from 9% to as
high as 50% (NCBI, n.d.).

Treatment
Transmission
The CCHF virus is transmitted to people either by tick bites or
through contact with infected animal blood or tissues during
and immediately after slaughter.
Human-to-human
transmissions occurred with contact with secretion, blood,
organs, or any other bodily fluids of an infected body. Hospitalacquired infections can also occur due to improper sterilization
of medical equipment, reuse of needles and contamination of
medical supplies (WHO, n.d.).

A minority of symptoms of CCHF

Protection
Protection of exposed skin around other infected animals
or other humans are the only option. Insect repellant is
may be used for the protection against of CCHF.
Individuals should also avoid close contact with the
blood and body fluids of livestock or humans who show
symptoms of infection. An inactivated, mouse-brain
derived vaccine against CCHF has been developed and is
used on a small scale in Eastern Europe. However, there
is no safe and effective vaccine currently available for
human use (CDC, 2014).

Being bitten by ticks, 61.3% stated they could recognize ticks and
56.1% stated that not all tick bites cause the disease. Seventy-seven
point eight percent stated CCHF is a virulent disease, 33.1% stated it
can be transmitted from human to human and 30.3% stated it can be
transmitted from animals to humans. (NCBI, February 11, 2015).
Because CCHF is a virus of the Bunyaviridae family or of any other
virus, there is no absolute cure but instead just intensive supportive
care. The antiviral drug called ribavirin has been used in the
treatment of CCHF patients reportedly with some benefit (WHO,
n.d.)
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